• Principal Investigator
  • Male

Prof. dr. E. Eldering

Position: Professor
Main activities: Research
Specialisation: Immuno-Hematology
foto E. Eldering is one of the AMC Principal Investigators
Focus of research:

The group of Eric Eldering at the Dept of Experimental Immunology of the AMC works on apoptosis regulation in normal and pathological immune cells. We apply cellular, biochemical and molecular biology techniques in human cells and mouse models, in two main research lines. The first concerns translational research into leukemia, driven by clinical problems, in close collaboration with prof Arnon Kater (Dept of Hematology, AMC). We have studied apoptosis (dys)regulation in B cells since 2002, subsequently focusing on Chronic Lymphocytic Leukemia (CLL). We currently study three aspects of CLL biology:
1. CLL functional genetics and molecular diagnostics
2. The leukemic micro-environment, apoptosis dysregulation and novel drugs
3. Interaction between the immune system and CLL with focus on immune metabolism


Second is a research line devoted to more fundamental immunological issues.We have studied the role of Bcl-2 family members in T and B cells during initiation of the immune response. Bcl-2 members Noxa and Mcl-1 control outgrowth of high affinity lymphocytes as well as clonal diversity. Currently we are studying interactions among Bcl-2 family members using a novel technique called BH3 mimetic profiling (Peperzak 2017). The ultimate goal of this research is to apply the insight obtained in novel vaccination and anti-cancer strategies.

In 2014, three NWO Veni laureates have started their own projects: Felix Wensveen studies selection of high affinity T and B cells (finished January 2017), Victor Peperzak investigates regulation of pro-survival Mcl-1 in malignant B cells (moved to UMC Utrecht in Nov 2015), and Rianne van der Windt studies Immunometabolism, which has become an integral part of our Hemato-Oncology research line.
 

AMC themes: Infection & Immunity, Oncology
Departments: Experimental Immunology, Internal Medicine: Clinical Haematology
Guikema JE, Amiot M, Eldering E, Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. EXPERT OPIN THER TAR 2017;21 (8):767-779 [PubMed]
Peperzak V, Slinger E, ter Burg J, Eldering E, Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. CELL DEATH DIFFER 2017;24 (1):111-119 [PubMed]
Slinger E, Thijssen R, Kater AP , Eldering E, Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. LEUKEMIA 2017;-:- [PubMed]
van Attekum MHA. Formation of a tumor-supportive microenvironment in chronic lymphocytic leukemia: Addressing the reciprocal interactions in the CLL—T cell—macrophage triad. S.l.: s.n.; 2017. 160p. ISBN 978-94-6182-754-8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): )
van Attekum MHA, Eldering E, Kater AP, Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. HAEMATOLOGICA 2017;102 (9):1469-1476 [PubMed]
van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP , Eldering E, Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. ONCOGENE 2017;36 (26):3651-3660 [PubMed]
van Attekum MHA, van Bruggen JAC, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP, CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. HAEMATOLOGICA 2017;ahead of print [PubMed]
Wensveen FM, Slinger E, van Attekum MHA, Brink R, Eldering E, Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling (vol 6, 35673, 2016). SCI REP-UK 2017;7:39366 [PubMed]
Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E, Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. HAEMATOLOGICA 2016;101 (9):e376-e377 [PubMed]
Thijssen R. The interplay between microenvironmental signaling and novel targeted drugs in CLL. S.l.: s.n.; 2016. 171p. ISBN 978-94-6182-733-3 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Eldering EF, Kater AP; copromotor(s): Kersten MJ)
Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 ( voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells (Vol 30, pg 337, 2016). LEUKEMIA 2016;30 (9):1963 [PubMed]
van Attekum MHA, Kater AP , Eldering E, The APRIL paradox in normal versus malignant B cell biology. CELL DEATH DIS 2016;7 (6):e2276 [PubMed]
van Attekum MHA, Terpstra S, Reinen E, Kater AP , Eldering E, Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling. CELL DEATH DISCOV 2016;2:16020 [PubMed]
Wensveen FM, Slinger E, van Attekum MHA, Brink R, Eldering E, Antigen-affinity controls pregerminal centser B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. SCI REP-UK 2016;6:35673 [PubMed]
Spaargaren M, de Rooij MFM, Kater AP , Eldering E, BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. ONCOGENE 2015;34 (19):2426-2436 [PubMed]
te Raa GD. Molecular characteristics and prognosis in CLL. S.l.: s.n.; 2015. 240p. ISBN 978-94-6182-531-5 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Eldering EF; copromotor(s): Kater AP)
te Raa GD, Derks IAM, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MHJ, Kater AP , Eldering E, The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 2015;29 (5):1133-1142 [PubMed]
te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP, Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. CELL DEATH DIS 2015;6:e1852 [PubMed]
Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. HAEMATOLOGICA 2015;100 (8):e302-e306 [PubMed]
Tonino SH, Mulkens CE, van Laar J, Derks IAM, Suo G, Croon-de Boer F, van Oers MHJ, Eldering E, Wang JY, Kater AP, Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2015;56 (8):2439-2447 [PubMed]
Vieira Braga FA, Hertoghs KML, Kragten NAM, Doody GM, Barnes NA, Remmerswaal EBM, Hsiao CC, Moerland PD, Wouters D, Derks IAM, van Stijn A, Demkes M, Hamann J, Eldering E, Nolte MA, Tooze RM, ten Berge IJM, van Gisbergen KPJM, van Lier RAW, Blimp-1 homolog Hobit identifies effector-type lymphocytes in humans. EUR J IMMUNOL 2015;45 (10):2945-2958 [PubMed]
Kater AP, Eldering E, miR in CLL: more than mere markers of prognosis?. BLOOD 2014;124 (1):2-4 [PubMed]
Kater AP, Spiering M, Liu RD, Doreen te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NAG, Luijks DM, Eldering E, van Oers MHJ, Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. LEUKEMIA RES 2014;38 (1):34-41 [PubMed]
te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRIT J HAEMATOL 2014;167 (4):565-569 [PubMed]
te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EBM, ten Berge IJM, van Lier RAW, Eldering E, van Oers MHJ, Tonino SH, Kater AP, CMV-specific CD8(+) T-cell function is not impaired in chronic lymphocytic leukemia. BLOOD 2014;123 (5):717-724 [PubMed]
Bruijn M, Lutter R, Eldering E, Bos AP, van Woensel JBM, Effect of oxidative stress on respiratory epithelium from children with Down syndrome. EUR RESPIR J 2013;42 (4):1037-1045 [PubMed]
de Weerdt I, Eldering E, van Oers MH, Kater AP, The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. LEUKEMIA RES 2013;37 (7):838-847 [PubMed]
Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JEJ, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MHJ, Eldering E, Medema JP, Kater AP, Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. BLOOD 2013;122 (24):3960-3963 [PubMed]
Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MHJ, Eldering E, CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. CELL DEATH DIS 2013;4:e782 [PubMed]
Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, van Attekum MHA, van Bochove GG, Luijks DM, Pals ST, van Lier RAW, Kater AP, van Oers MHJ, Eldering E, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. BLOOD 2013;122 (17):3010-3019 [PubMed]
te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2013;54 (8):1849-1853 [PubMed]
Wensveen FM, Geest CR, Libregts SFWM, Derks IAM, Ekert PG, Labi V, Villunger A, Nolte MA, Eldering E, BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. APOPTOSIS 2013;18 (11):1306-1318 [PubMed]
Wensveen FM, Klarenbeek PL, van Gisbergen KPJM, Pascutti MF, Derks IAM, van Schaik BDC, ten Brinke A, de Vries N, Cekinovic D, Jonjic S, van Lier RAW, Eldering E, Pro-apoptotic protein Noxa regulates memory T cell population size and protects against lethal immunopathology. J IMMUNOL 2013;190 (3):1180-1191 [PubMed]
de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. BLOOD 2012;119 (11):2590-2594 [PubMed]
Helbig C, Gentek R, Backer RA, de Souza Y, Derks IAM, Eldering E, Wagner K, Jankovic D, Gridley T, Moerland PD, Flavell RA, Amsen D, Notch controls the magnitude of T helper cell responses by promoting cellular longevity. P NATL ACAD SCI USA 2012;109 (23):9041-9046 [PubMed]
Heutinck KM, Rowshani AT, Kassies J, Claessen N, van Donselaar-van der Pant KAMI, Bemelman FJ, Eldering E, van Lier RAW, Florquin S, ten Berge IJM, Hamann J, Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells. KIDNEY INT 2012;82 (6):664-675 [PubMed]
Jak M. Microenvironment and anti-CD20 based therapies in CLL. s.l.: s.n.; 2012. 169p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, van Lier RAW; copromotor(s): Eldering E)
Tromp JM. The microenvironment and treatment resistance in chronic lymphocytic leukemia. s.l.: s.n.; 2012. 183p. ISBN 9789090269375 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Eldering EF; copromotor(s): )
Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MHJ, Eldering E, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. CLIN CANCER RES 2012;18 (2):487-498 [PubMed]
Wensveen FM, Derks IAM, van Gisbergen KPJM, de Bruin AM, Meijers JCM, Yigittop H, Nolte MA, Eldering E, van Lier RAW, BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. BLOOD 2012;119 (6):1440-1449 [PubMed]
Wensveen FM, Unger PPA, Kragten NAM, Derks IAM, ten Brinke A, Arens R, van Lier RAW, Eldering E, van Gisbergen KPJM, CD70-Driven Costimulation Induces Survival or Fas-Mediated Apoptosis of T Cells Depending on Antigenic Load. J IMMUNOL 2012;188 (9):4256-4267 [PubMed]
Wensveen FM, van Gisbergen KPJM, Eldering E, The fourth dimension in immunological space: how the struggle for nutrients selects high-affinity lymphocytes. IMMUNOL REV 2012;249 (1):84-103 [PubMed]
Guadagnoli M, Kimberley F, Phan U, Cameron K, Vink P, Rodermond H, Eldering E, Kater A, van Eenennaam H, Medema JP, Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. BLOOD 2011;117 (25):6856-6865 [PubMed]
Jak M, van Bochove GGW, Reits EA, Kallemeijn WW, Tromp JM, Umana P, Klein C, van Lier RAW, van Oers MHJ, Eldering E, CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. BLOOD 2011;118 (19):5178-5188 [PubMed]
Jak M, van Bochove GGW, van Lier RAW, Eldering E, van Oers MHJ, CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. LEUKEMIA 2011;25 (6):968-978 [PubMed]
Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater AP, Mertens D, te Raa D, Döhner H, Stilgenbauer S, Zenz T, DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. BLOOD 2011;117 (5):1622-1632 [PubMed]
Tonino SH. Targets for the treatment of drug resistant chronic lymphocytic leukemia. s.l.: s.n.; 2011. 175p. ISBN 9789090264820 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ; copromotor(s): Kater AP , Eldering E)
Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP, ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. ONCOGENE 2011;30 (6):701-713 [PubMed]
van Gisbergen KPJM, Klarenbeek PL, Kragten NAM, Unger PPA, Nieuwenhuis MBB, Wensveen FM, ten Brinke A, Tak PP, Eldering E, Nolte MA, van Lier RAW, The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants. IMMUNITY 2011;35 (1):97-108 [PubMed]
Wensveen FM, Alves NL, Derks IAM, Reedquist KA, Eldering E, Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1. APOPTOSIS 2011;16 (7):708-721 [PubMed]
Zeilstra J, Joosten SPJ, Wensveen FM, Dessing MC, Schütze DM, Eldering E, Spaargaren M, Pals ST, WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. BIOCHEM BIOPH RES CO 2011;406 (1):1-6 [PubMed]
Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, Majid A, Eldering E, Dyer MJS, Cohen GM, Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. HAEMATOLOGICA 2010;95 (9):1510-1518 [PubMed]
Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, Prakken BJ, Maslinski W, Eldering E, Tak PP, Reedquist KA, Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue. J IMMUNOL 2010;184 (5):2718-2728 [PubMed]
Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IAM, Dolman KM, Beaumont T, Tedder TF, van Noesel CJM, Eldering E, van Lier RAW, CD20 deficiency in humans results in impaired T cell-independent antibody responses. J CLIN INVEST 2010;120 (1):214-222 [PubMed]
Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP, R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. LEUKEMIA 2010;24 (3):652-654 [PubMed]
Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP , van Lier RAW, van Oers MHJ, Eldering E, Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. ONCOGENE 2010;29 (36):5071-5082 [PubMed]
Wensveen FM. Survival of the fittest clone. Pro-apoptotic protein Noxa controls of lymphocytes under competitive conditions. s.l.: s.n.; 2010. 198p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Lier RAW; copromotor(s): Eldering EF)
Wensveen FM, van Gisbergen KPJM, Derks IAM, Gerlach C, Schumacher TN, van Lier RAW, Eldering E, Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones. IMMUNITY 2010;32 (6):754-765 [PubMed]
Abreu JRF, Grabiec AM, Krausz S, Spijker R, Burakowski T, Maslinski W, Eldering E, Tak PP, Reedquist KA, The Presumed Hyporesponsive Behavior of Rheumatoid Arthritis T Lymphocytes Can Be Attributed to Spontaneous Ex Vivo Apoptosis rather than Defects in T Cell Receptor Signaling. J IMMUNOL 2009;183 (1):621-630 [PubMed]
Jak M, Mous R, Remmerswaal EBM, Spijker R, Jaspers A, Yagüe A, Eldering E, van Lier RAW, van Oers MHJ, Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2009;50 (5):788-801 [PubMed]
Mous R, Jaspers A, Luijks DMP, Mellink CHM, van Oers MHJ, Kater AP , Eldering E, Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. LEUKEMIA 2009;23 (7):1352-1355 [PubMed]
Pasero C, Barbarat B, Just-Landi S, Bernard A, Aurran-Schleinitz T, Rey J, Eldering E, Truneh A, Costello RT, Olive D, A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production. EUR J IMMUNOL 2009;39 (9):2502-2514 [PubMed]
Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MHJ, Mertens D, Döhner H, Stilgenbauer S, miR-34a as part of the resistance network in chronic lymphocytic leukemia. BLOOD 2009;113 (16):3801-3808 [PubMed]
Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MHJ, Mellink CHM, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS, Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J MOL DIAGN 2008;10 (5):442-451 [PubMed]
Hallaert DYH. 'From the cradle to the grave' : novel therapeutic approaches to attack the microenvironment in chronic lymphocytic leukemia. s.l.: s.n.; 2008. 171p. ISBN 9789090235479 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MH; copromotor(s): Eldering E)
Hallaert DYH, Jaspers A, van Noesel CJ, van Oers MHJ, Kater AP, Eldering E, c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. BLOOD 2008;112 (13):5141-5149 [PubMed]
Mous R. Studies on the immune system in CLL.. s.l.: s.n.; 2008. 165p. ISBN 9789088910623 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, van Lier RAW; copromotor(s): Eldering EF)
Mous R, Savage P, Eldering E, Teeling P, van Oers MH, van Lier RA, Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. LEUKEMIA LYMPHOMA 2008;49 (8):1592-1602 [PubMed]
van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F, In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. CANCER RES 2008;68 (24):10137-10144 [PubMed]
Alves NL. 'How to keep T-cells alive and kicking': studies on extra-cellular cues and intra-cellular pathways involved in maintaining a dynamic T cell compartement. s.l.: s.n.; 2007. 175p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Lier RAW; copromotor(s): Eldering EF, Arosa FA)
Alves NL, van Lier RAW, Eldering E, Withdrawal symptoms on display: Bcl-2 members under investigation. TRENDS IMMUNOL 2007;28 (1):26-32 [PubMed]
Hallaert DYH, Spijker R, Jak M, Derks IAM, Alves NL, Wensveen FM, de Boer JP, de Jong D, Green SR, van Oers MHJ, Eldering E, Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. CELL DEATH DIFFER 2007;14 (11):1958-1967 [PubMed]
Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, de Boer JP, Verheij M, van Ostrom C, de Vries A, van't Veer L, de Jong D, In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. BLOOD 2007;110 (4):1116-1122 [PubMed]
Smit LA, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MHJ, van Noesel CJM, Eldering E, Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. BLOOD 2007;109 (4):1660-1668 [PubMed]
van Oosterwijk MF, Juwana H, Arens R, Tesselaar K, van Oers MHJ, Eldering E, van Lier RAW, CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. INT IMMUNOL 2007;19 (6):713-718 [PubMed]
Alves NL, Derks IAM, Berk E, Spijker R, van Lier RAW, Eldering E, The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. IMMUNITY 2006;24 (6):703-716 [PubMed]
Kater AP. Novel apoptosis inducting strategies in chronic lymphocytic leukemia. S.l.: s.n.; 2006. 208p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, Kipps TJ; copromotor(s): Eldering E)
Mous R, Savage P, Remmerswaal EBM, van Lier RAW, Eldering E, van Oers MHJ, Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. LEUKEMIA 2006;20 (6):1096-1102 [PubMed]
Eldering E, VanLier RAW, B-cell antigen receptor-induced apoptosis: looking for clues. IMMUNOL LETT 2005;96 (2):187-194 [PubMed]
Mackus WJM, Kater AP , Grummels A, Evers LM, Hooijbrink B, Kramer MHH, Castro JE, Kipps TJ, van Lier RAW, van Oers MHJ, Eldering E, Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. LEUKEMIA 2005;19 (3):427-434 [PubMed]
Bos IGA, Lubbers YTP, Eldering E, Abrahams JP, Hack CE, Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor. BBA-PROTEINS PROTEOM 2004;1699 (1-2):139-144 [PubMed]
Eldering E, Mackus WJM, Derks IAM, Evers LM, Beuling E, Teeling P, Lens SMA, van Oers MHJ, van Lier RAW, Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase-9 activation. EUR J IMMUNOL 2004;34 (7):1950-1960 [PubMed]
Hess CJ, Denkers F, Ossenkoppele GJ, Waisfisz Q, McElgunn CJ, Eldering E, Schouten JP, Schuurhuis GJ, Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. LEUKEMIA 2004;18 (12):1981-1988 [PubMed]
Kater AP, Evers LM, Remmerswaal EBM, Jaspers A, Oosterwijk MF, van Lier RAW, van Oers MHJ, Eldering E, CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. BRIT J HAEMATOL 2004;127 (4):404-415 [PubMed]
Kater AP, Remmerswaal EBM, Nolte MA, Eldering E, van Oers MHJ, van Lier RAW, Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. BRIT J HAEMATOL 2004;126 (4):512-516 [PubMed]
Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gómez-Caro R, Alvarez-Mon M, de Jong J, Eldering E, Martínez-A C, Medema JP, Hahne M, APRIL promotes B-1 cell-associated neoplasm. CANCER CELL 2004;6 (4):399-408 [PubMed]
Werner AB, Tait SWG, de Vries E, Eldering E, Borst J, Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J BIOL CHEM 2004;279 (27):28771-28780 [PubMed]
Arkenbout EK, van Bragt M, Eldering E, van Bree C, Grimbergen JM, Quax PHA, Pannekoek H, de Vries CJM, TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest. ARTERIOSCL THROM VAS 2003;23 (9):1535-1540 [PubMed]
Bos GAC. C1-inhibitor potentiation by glycosaminoglycans. S.l.: s.n.; 2003. 144p. ISBN 90-9017386-2 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Hack CE, Abrahams JP; copromotor(s): Eldering EF)
Bos IGA, de Bruin EC, Karuntu YA, Modderman PW, Eldering E, Hack CE, Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor. BBA-PROTEINS PROTEOM 2003;1648 (1-2):75-83 [PubMed]
Bos IGA, Lubbers YTP, Roem D, Abrahams JP, Hack CE, Eldering E, The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. J BIOL CHEM 2003;278 (32):29463-29470 [PubMed]
Eldering E, Spek CA, Aberson HL, Grummels A, Derks IA, de Vos AF, McElgunn CJ, Schouten JP, Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. NUCLEIC ACIDS RES 2003;31 (23):e153 [PubMed]
Mackus WJM. Antigen receptor triggering and apotopic pathways in neoplastic B cells. S.l.: s.n.; 2003. 139p. ISBN 90-6734-049-92 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Oers MHJ, van Lier RAW; copromotor(s): Eldering EF)
Leeksma OC, van Achterberg TAE, Tsumura Y, Toshima J, Eldering E, Kroes WGM, Mellink C, Spaargaren M, Mizuno K, Pannekoek H, de Vries CJM, Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. EUR J BIOCHEM 2002;269 (10):2546-2556 [PubMed]
Mackus WJM, Lens SMA, Medema RH, Kwakkenbos MJ, Evers LM, Oers MHJv, van Lier RAW, Eldering E, Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. INT IMMUNOL 2002;14 (9):973-982 [PubMed]
van der Kolk LE, Evers LM, Omene C, Lens SMA, Lederman S, van Lier RAW, van Oers MHJ, Eldering E, CD20-induced B cell death can bypass mitochondria and caspase activation. LEUKEMIA 2002;16 (9):1735-1744 [PubMed]
Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H, Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries. J MOL BIOL 2001;305 (4):773-783 [PubMed]
Stoop AA, Jespers L, Lasters I, Eldering E, Pannekoek H, High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). J MOL BIOL 2000;301 (5):1135-1147 [PubMed]
Gårdsvoll H, van Zonneveld AJ, Holm A, Eldering E, van Meijer M, Danø K, Pannekoek H, Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. FEBS LETT 1998;431 (2):170-174 [PubMed]
Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE, Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J IMMUNOL 1997;159 (4):1953-1960 [PubMed]
Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE, Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J BIOL CHEM 1996;271 (22):12913-12918 [PubMed]
Zahedi R, Aulak KS, Eldering E, Davis AE 3rd, Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251. J BIOL CHEM 1996;271 (39):24307-24312 [PubMed]
Eldering E, Verpy E, Roem D, Meo T, Tosi M, COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J BIOL CHEM 1995;270 (6):2579-2587 [PubMed]
Verpy E, Couture-Tosi E, Eldering E, Lopez-Trascasa M, Späth P, Meo T, Tosi M, Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J CLIN INVEST 1995;95 (1):350-359 [PubMed]
Aulak KS, Eldering E, Hack CE, Lubbers YP, Harrison RA, Mast A, Cicardi M, Davis AE 3rd, A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J BIOL CHEM 1993;268 (24):18088-18094 [PubMed]
Eldering E, Huijbregts CC, Nuijens JH, Hack CE, The balance between inhibition and substrate-type reactions of recombinant C1 inhibitor P5/P3 variants. BEHRING INST MITT 1993;93 (-):125-130 [PubMed]
Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, Hack CE, Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J CLIN INVEST 1993;91 (3):1035-1043 [PubMed]
Davis AE 3rd, Aulak K, Parad RB, Stecklein HP, Eldering E, Hack CE, Kramer J, Strunk RC, Bissler J, Rosen FS, C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. NAT GENET 1992;1 (5):354-358 [PubMed]
Eldering E, Huijbregts CC, Lubbers YT, Longstaff C, Hack CE, Characterization of recombinant C1 inhibitor P1 variants. J BIOL CHEM 1992;267 (10):7013-7020 [PubMed]
Eldering E, Nuijens JH, Hack CE, Expression of functional human C1 inhibitor in COS cells. J BIOL CHEM 1988;263 (24):11776-11779 [PubMed]
Key publications

Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, van Attekum MHA, van Bochove GG, Luijks DM, Pals ST, van Lier RAW, Kater AP, van Oers MHJ, Eldering E, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. BLOOD 2013;122 (17):3010-3019 [PubMed]
Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MHJ, Eldering E, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. CLIN CANCER RES 2012;18 (2):487-498 [PubMed]
te Raa GD, Derks IAM, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MHJ, Kater AP , Eldering E, The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 2015;29 (5):1133-1142 [PubMed]
Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. HAEMATOLOGICA 2015;100 (8):e302-e306 [PubMed]


All Publications

Research programmes

Apoptosis regulation in immuno-hematology

Themes: Infection and Immunity and Oncology
 

Faculty
Prof. dr. E. Eldering
Z. Chen PhD
Prof. dr. A.P. Kater MD PhD

Postdocs
Dr. V. Peperzak
Dr. E. Slinger
Dr. S.H. Tonino MD PhD
Dr. F.M. Wensveen PhD
Dr. G.J.W. van der Windt

PhD Students
F. Brocco
Z. Chen PhD
R. Delgado MSc
M.V. Haselager
T. Hofland MSc
A.C. Leeksma MD
I. de Weerdt MD

Others
Drs. J. ter Burg
Ing. I.A.M. Derks
D.M.P. Luijks
Drs. S. Terpstra

Other research related activities
  • None reported
Current research funding
  • AMC
  • Celgene Corporation
  • Europese Unie
  • Gilead Sciences, Inc.
  • KWF Kankerbestrijding
  • Roche Glycart AG
  • Stichting AMC Foundation (Vrijgesteld)
  • ZonMw